Joseph Baroldi Biography and Net Worth

EVP & Chief Business Officer of Ionis Pharmaceuticals

Mr. Baroldi is our executive vice president and chief business officer. As a member of the executive leadership team, he is responsible for leading and providing strategic guidance for Ionis’ business development and alliance management activities.

Mr. Baroldi has more than two decades of industry experience. Prior to Ionis, he was chief operating officer at Avidity Biosciences, where he played an integral role in their initial public offering and building their team. Previously, he was vice president, business development at Ionis, where he held several roles of increasing responsibility over 10 years. Before that Mr. Baroldi held positions in strategic planning and scientific research.

Mr. Baroldi holds an M.B.A. from the Rady School of Management at the University of California-San Diego. He received his B.S. in Biological Sciences from the University of California-Irvine.

What is Joseph Baroldi's net worth?: The estimated net worth of Joseph Baroldi is at least $831,569.16 as of April 16th, 2024. Mr. Baroldi owns 19,631 shares of Ionis Pharmaceuticals stock worth more than $831,569 as of September 18th. This net worth approximation does not reflect any other investments that Mr. Baroldi may own. Learn More about Joseph Baroldi's net worth.
How do I contact Joseph Baroldi?: The corporate mailing address for Mr. Baroldi and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Joseph Baroldi's contact information.
Has Joseph Baroldi been buying or selling shares of Ionis Pharmaceuticals?: Joseph Baroldi has not been actively trading shares of Ionis Pharmaceuticals during the last ninety days. Most recently, Joseph Baroldi sold 4,006 shares of the business's stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a transaction totalling $166,649.60. Following the completion of the sale, the executive vice president now directly owns 19,631 shares of the company's stock, valued at $816,649.60. Learn More on Joseph Baroldi's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Allene Diaz (Director), Richard Geary (EVP), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), and Eric Swayze (EVP). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, insiders at the sold shares 27 times. They sold a total of 283,235 shares worth more than $14,115,564.62. The most recent insider tranaction occured on August, 28th when EVP Richard S Geary sold 320 shares worth more than $15,731.20. Insiders at Ionis Pharmaceuticals own 2.7% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 8/28/2024.

Joseph Baroldi Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/16/2024	Sell	4,006	$41.60	$166,649.60	19,631

Joseph Baroldi Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $42.36

$41.27

$43.00

50 Day Range

MA: $47.47

$40.70

$51.86

2 Week Range

Now: $42.36

$35.95

$54.44

Volume

1,485,012 shs

Average Volume

1,296,410 shs

Market Capitalization

$6.18 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39

Tim Sykes’ Urgent Trade Alert: “Make this move now”

From Timothy Sykes | Ad

WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…

Click here to see a unique election-year trade